Cristina Alli

IRBM Science Park — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index1.0kcitations28works0.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Microtubule and mitosis dynamics(15), Cancer-related Molecular Pathways(6), Protein Tyrosine Phosphatases(6), Bioactive Compounds and Antitumor Agents(6), Cancer Treatment and Pharmacology(5)

Publications28 total

Cyclic Peptide Inhibitors of the MLH1-MSH3 Interaction as a Potential Therapeutic Strategy for Huntington's Disease
2026Open Access
An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse models
Nature Communications·2026Open Access
Novel azabicyclic series of potent SHP2 allosteric inhibitors
Bioorganic & Medicinal Chemistry Letters·2025
Abstract 1975: Discovery of I-1000233, a potent, selective and brain permeable SHP2 allosteric inhibitor
Cancer Research·2024
Direct-to-biology platform: From synthesis to biological evaluation of SHP2 allosteric inhibitors
Bioorganic & Medicinal Chemistry Letters·2024· 5 citedOpen Access
Direct-to-Biology Platform: From Synthesis to Biological Evaluation of Shp2 Allosteric Inhibitors
SSRN Electronic Journal·2024Open Access
Discovery of a Novel Series of Potent SHP2 Allosteric Inhibitors
ACS Medicinal Chemistry Letters·2023· 11 citedOpen Access
Supplementary Methods, Figure Legends 1-8, Tables 1-4 from NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
2023Open Access
Data from NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
2023Open Access
Data from NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
2023Open Access
Supplementary Figures 1-8 from NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
2023Open Access
Supplementary Methods, Figure Legends 1-8, Tables 1-4 from NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
2023Open Access
Supplementary Figures 1-8 from NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
2023Open Access
Data from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Supplementary Fig. S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Supplementary Table S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Supplementary Fig. S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Supplementary Table S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Data from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
2023Open Access
Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors
ACS Medicinal Chemistry Letters·2023· 16 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Enrico Pesenti(16), Maria Laura Giorgini(15), Paolo Cappella(15), Dario Ballinari(15), Laura Gianellini(14), Maurizio Rocchetti(14), Valter Croci(9), Paola Vianello(9), Carlo Toniatti(9), Patrizia Carpinelli(8), Paola Storici(8), Paola Zugnoni(8), Chiara Soncini(8), Aurelio Marsiglio(8), Daniele Fancelli(8), Barbara Valsasina(8), Antonella Ciavolella(8), Francesco Fiorentini(8), Arturo Galvani(8), Antonella Isacchi(8)